Pharmaceuticals, Biotechnology and Life Sciences
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy…
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board…
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug…
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort…
KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; “BGMS” or…
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology…
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing…
Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial…
Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after…